The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis
- First Online:
- 632 Downloads
Botulinum toxin type A (BoNTA) is a neurotoxin that acts by inhibiting the release of neurotransmitters acetylcholine at neuromuscular junctions, thus reducing muscular contractions. Recent evidence suggests that BoNTA can reduce nociceptive activities of sensory neurons in animal models by inhibiting release of certain neuropeptides. Despite the therapeutic benefit of BoNTA in alleviating painful muscle spasms, its efficacy in other musculoskeletal pain conditions is less clear.
We aim to examine the efficacy of BoNTA in reducing chronic musculoskeletal pain.
Studies for inclusion in our report were identified using MEDLINE, EMBASE, PUBMED, Cochrane Central Register of Controlled Trials, CINAHL, and reference lists of relevant articles. Studies were considered eligible for inclusion if they were randomized controlled trials (RCTs), evaluating the efficacy of BoNTA injections in pain reduction. All studies were assessed and data were abstracted independently by paired reviewers. The outcome measures were baseline and final pain scores as assessed by the patients. The internal validity of trials was assessed with the Jadad scale. Disagreements were resolved through discussions.
Twenty-one studies were included in the systematic review and 15 of them were included in the final meta-analysis. There was a total of 706 patients in the meta-analysis, represented from trials of plantar fasciitis (n = 1), tennis elbow (n = 2), shoulder pain (n = 1), whiplash (n = 3), and myofascial pain (n = 8). Overall, there was a small to moderate pain reduction among BoNTA patients when compared to control (SMD = −0.27, 95% CI: −0.44 to −0.11). When the results were analyzed in subgroups, only tennis elbow (SMD = −0.44, 95% CI: −0.86 to −0.01) and plantar fasciitis (SMD = −1.04, 95% CI: −1.68 to −0.40) demonstrated significant pain relief. Although not in the meta-analysis, one back pain study also demonstrated positive results for BoNTA. Lastly, BoNTA was effective when used at ≥25 units per anatomical site or after a period ≥5 weeks.
In our meta-analysis, BoNTA had a small to moderate analgesic effect in chronic musculoskeletal pain conditions. It was particularly effective in plantar fasciitis, tennis elbow, and back pain, but not in whiplash or shoulder pain patients. However, more evidence is required before definitive conclusions can be drawn. On the other hand, there is convincing evidence that BoNTA lacks strong analgesic effects in patients with myofascial pain syndrome. A general dose-dependent and temporal response with BoNTA injections was also observed.
KeywordsBotox Botulinum toxin type A (BoNTA) Musculoskeletal diseases Pain Plantar fasciitis Tennis elbow Shoulder pain Whiplash Myofascial pain RCT Systematic review Meta-analysis
- Cohen J (1988) Statistical Power Analysis in the Behavioral Sciences, 2nd edn Lawrence Erlbaum Associates, Inc., Hillsdale (NJ)Google Scholar
- Compendium of Pharmaceuticals and Specialties (2010) Webcom inc, Toronto 407 –410, Online http://www.e-cps.ca
- Esenyel M, Aldemir T, Gursoy E, Esenyel CZ, Demir S, Durmusoglu G (2007) Myofascial pain syndrome: efficacy of different therapies. J Back Musculoskelet Rehabil 20:43–47Google Scholar
- Flanders M, Tischler A, Wise J, Williams F, Beneish R, Auger N (1987) Injection of type A botulinum toxin into extraocular muscles for correction of strabismus. Can J Ophtalmol 22(4):212–217Google Scholar
- Gobel H, Heinze A, Reichel G, Hefter H, Benecke R (2006) Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 125(1–2):82–88CrossRefPubMedGoogle Scholar
- Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G (2008) Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. J Craniomandibular Pract 26(2):126–135Google Scholar
- Lang AM (2000) A pilot study of botulinum toxin type A (Botox), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manag 10:108–112Google Scholar
- National Institute of Health (1998) NIH Guide: new directions in pain research I. Sept 4, available from http://www.grants.nih.gov/grants/guide/pa-files/PA-98-102.html
- Odergrena T, Hjaltasona H, Kaakkolab H, Soldersc G, Hankod J, Fehlingd C, Marttilae RJ, Lundhf H, Geding S, Westergreng I, Richardsonh A, Dotth C, Cohenh H (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatr 64:6–12CrossRefGoogle Scholar
- Review Manager (RevMan) (2008) (Computer program). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane CollaborationGoogle Scholar
- Royal MA, Gunyea I, Bhakta B, Movva V, Ward S, Jenson M (2001) Botulinum toxin type A in the treatment of refractory myofascial pain (abstract). Neurology 56(Suppl 3):A350Google Scholar
- Simons DG, Travell JG, Simons LS (1999) Myofascial pain and dysfunction: The trigger point manual. 2nd edn. Upper half of body, vol. 1, Williams & Wilkins, Baltimore (MD)Google Scholar
- Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26(Suppl 56):18–24Google Scholar
- Sohling M (2002) Treatment of myofascial pain of the shoulder and neck region with botulinum toxin A. Naunyn-Schmiedeberg’s Arch Pharmacol 365(2):R42Google Scholar
- Szczepanska-Szerej A, Stepniak C, Szczepanski L (2003) Clinical evaluation of botulinum toxin A in the treatment of pain in patients with fibromyalgia. Reumatologia 41(4):335–340Google Scholar